Skip to main content
Erschienen in: Journal of Clinical Immunology 4/2014

01.05.2014 | Original Research

First Report on the Moroccan Registry of Primary Immunodeficiencies: 15 Years of Experience (1998–2012)

verfasst von: A. A. Bousfiha, L. Jeddane, N. El Hafidi, N. Benajiba, N. Rada, J. El Bakkouri, A. Kili, S. Benmiloud, I. Benhsaien, I. Faiz, O. Maataoui, Z. Aadam, A. Aglaguel, L. Ait Baba, Z. Jouhadi, R. Abilkassem, M. Bouskraoui, M. Hida, J. Najib, H. Salih Alj, F. Ailal, For the Moroccan Society for Primary Immunodeficiencies (MSPID)

Erschienen in: Journal of Clinical Immunology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary immunodeficiencies (PIDs) are a large group of diseases characterized by susceptibility to infections. We provide the first comprehensive report on PIDs in Morocco, the epidemiological, clinical, etiological and outcome features which have never before been described.

Methods

A national registry was established in 2008, grouping together data for PID patients diagnosed since 1998.

Results

In total, 421 patients were diagnosed between 1998 and 2012. Parental consanguinity was common (recorded for 43.2 % of patients) and the median time to diagnosis was 2.0 years. Overall, 27.4 % of patients were considered to have well defined syndromes with immunodeficiency (48 cases of hyper-IgE syndrome and 40 of ataxia-telangiectasia); 22.7 % had predominantly antibody deficiencies (29 cases of agammaglobulinemia and 24 of CVID); 20.6 % had combined immunodeficiencies (37 cases of SCID and 26 of MHC II deficiencies) and 17.5 % had phagocyte disorders (14 cases of SCN and 10 of CGD). The principal clinical signs were lower respiratory tract infections (60.8 %), skin infections (33.5 %) and candidiasis (26.1 %). Mortality reached 28.8 %, and only ten patients underwent bone marrow transplantation. We analyzed the impact on mortality of residence, family history, parental consanguinity, date of diagnosis and time to diagnosis, but only date of diagnosis had a significant effect.

Conclusions

The observed prevalence of PID was 0.81/100,000 inhabitants, suggesting considerable underdiagnosis and a need to increase awareness of these conditions in Morocco. The distribution of PIDs was different from that reported in Western countries, with a particularly high proportion of SCID, MHC II deficiencies, hyper-IgE syndrome and autosomal recessive agammaglobulinemia. However, we have now organized a national network, which should improve diagnosis rates in remote regions.
Literatur
1.
Zurück zum Zitat Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2011;2:54. doi:10.3389/fimmu.2011.00054.PubMedCentralPubMedCrossRef Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2011;2:54. doi:10.​3389/​fimmu.​2011.​00054.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Ehlayel MS, Bener A, Laban MA. Primary immunodeficiency diseases in children: 15 year experience in a tertiary care medical center in Qatar. J Clin Immunol. 2013;33:317–24.PubMedCrossRef Ehlayel MS, Bener A, Laban MA. Primary immunodeficiency diseases in children: 15 year experience in a tertiary care medical center in Qatar. J Clin Immunol. 2013;33:317–24.PubMedCrossRef
4.
Zurück zum Zitat Naamane H, El Maataoui O, Ailal F, Barakat A, Bennani S, Najib J, et al. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr. 2010;169(9):1069–74.PubMedCrossRef Naamane H, El Maataoui O, Ailal F, Barakat A, Bennani S, Najib J, et al. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr. 2010;169(9):1069–74.PubMedCrossRef
5.
Zurück zum Zitat Joshi AY, Iyer VN, Hagan JB, Sauver JLS, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22.PubMedCentralPubMedCrossRef Joshi AY, Iyer VN, Hagan JB, Sauver JLS, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27:497–502.PubMedCrossRef Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27:497–502.PubMedCrossRef
7.
Zurück zum Zitat Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27:517–24.PubMedCrossRef Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27:517–24.PubMedCrossRef
8.
Zurück zum Zitat CEREDIH. The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135:264–72.CrossRef CEREDIH. The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135:264–72.CrossRef
9.
Zurück zum Zitat Leiva LE, Zelazco M, Oleastro M, Carneiro-Sampaio M, Condino-Neto A, Tavares Costa-Carvalho B, et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID Registry. J Clin Immunol. 2007;27(1):101–8.PubMedCrossRef Leiva LE, Zelazco M, Oleastro M, Carneiro-Sampaio M, Condino-Neto A, Tavares Costa-Carvalho B, et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID Registry. J Clin Immunol. 2007;27(1):101–8.PubMedCrossRef
10.
Zurück zum Zitat Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26(6):519–32.PubMedCrossRef Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26(6):519–32.PubMedCrossRef
11.
Zurück zum Zitat Barbouche MR, Galal N, Ben Mustapha I, Jeddane L, Mellouli F, Ailal F, et al. Primary immunodeficiencies in highly consanguineous North African populations. Ann N Y Acad Sci. 2011;1238:42–52.PubMedCrossRef Barbouche MR, Galal N, Ben Mustapha I, Jeddane L, Mellouli F, Ailal F, et al. Primary immunodeficiencies in highly consanguineous North African populations. Ann N Y Acad Sci. 2011;1238:42–52.PubMedCrossRef
12.
Zurück zum Zitat Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31:968–76.PubMedCrossRef Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31:968–76.PubMedCrossRef
14.
Zurück zum Zitat Jeddane L, Ailal F, Dubois-d’Enghien C, Abidi O, Benhsaien I, Kili A, et al. Molecular defects in Moroccan patients with ataxia-telangiectasia. NeuroMolecular Med. 2013;15(2):288–94.PubMedCrossRef Jeddane L, Ailal F, Dubois-d’Enghien C, Abidi O, Benhsaien I, Kili A, et al. Molecular defects in Moroccan patients with ataxia-telangiectasia. NeuroMolecular Med. 2013;15(2):288–94.PubMedCrossRef
17.
Zurück zum Zitat El-Maataoui O, Ailal F, Naamane H, Benhsaien I, Jeddane L, Farouqi B, et al. Immunophenotyping of severe combined immunodeficiency in Morocco. Immunol Anal Biol Spécialisée. 2011. doi:10.1016/j.immbio.2011.05.002. El-Maataoui O, Ailal F, Naamane H, Benhsaien I, Jeddane L, Farouqi B, et al. Immunophenotyping of severe combined immunodeficiency in Morocco. Immunol Anal Biol Spécialisée. 2011. doi:10.​1016/​j.​immbio.​2011.​05.​002.
18.
Zurück zum Zitat Ganiou Tidjani K, Ailal F, Najib J, Bellanné-Chantelot C, Donadieu J, Bousfiha AA. Intermittent chronic neutropenia in a patient with familial Mediterranean fever. Pediatr Blood Cancer. 2008;51(5):701–3.PubMedCrossRef Ganiou Tidjani K, Ailal F, Najib J, Bellanné-Chantelot C, Donadieu J, Bousfiha AA. Intermittent chronic neutropenia in a patient with familial Mediterranean fever. Pediatr Blood Cancer. 2008;51(5):701–3.PubMedCrossRef
19.
Zurück zum Zitat Ehlayel M, de Beaucoudrey L, Fike F, Nahas SA, Feinberg J, Casanova JL, et al. Simultaneous presentation of 2 rare hereditary immunodeficiencies: IL-12 receptor beta1 deficiency and ataxia-telangiectasia. J Allergy Clin Immunol. 2008;122(6):1217–9.PubMedCrossRef Ehlayel M, de Beaucoudrey L, Fike F, Nahas SA, Feinberg J, Casanova JL, et al. Simultaneous presentation of 2 rare hereditary immunodeficiencies: IL-12 receptor beta1 deficiency and ataxia-telangiectasia. J Allergy Clin Immunol. 2008;122(6):1217–9.PubMedCrossRef
20.
Zurück zum Zitat Al-Herz W. Primary immunodeficiency disorders in Kuwait: first report from Kuwait National Primary Immunodeficiency Registry (2004–2006). J Clin Immunol. 2008;28(2):186–93.PubMedCrossRef Al-Herz W. Primary immunodeficiency disorders in Kuwait: first report from Kuwait National Primary Immunodeficiency Registry (2004–2006). J Clin Immunol. 2008;28(2):186–93.PubMedCrossRef
21.
Zurück zum Zitat Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M, et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood. 2011;118(19):5108–18.PubMedCrossRef Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M, et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood. 2011;118(19):5108–18.PubMedCrossRef
22.
Zurück zum Zitat Al-Herz W, Alsmadi O, Melhem M, Recher M, Frugoni F, Notarangelo LD. Major histocompatibility complex class II deficiency in Kuwait: clinical manifestations, immunological findings and molecular profile. J Clin Immunol. 2013;33(3):513–9.PubMedCrossRef Al-Herz W, Alsmadi O, Melhem M, Recher M, Frugoni F, Notarangelo LD. Major histocompatibility complex class II deficiency in Kuwait: clinical manifestations, immunological findings and molecular profile. J Clin Immunol. 2013;33(3):513–9.PubMedCrossRef
23.
Zurück zum Zitat Altare F, Ensser A, Breiman A, Reichenbach J, Baghdadi JE, Fischer A, et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis. 2001;184(2):231–6.PubMedCrossRef Altare F, Ensser A, Breiman A, Reichenbach J, Baghdadi JE, Fischer A, et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis. 2001;184(2):231–6.PubMedCrossRef
24.
Zurück zum Zitat Fathallah DM, Jamal T, Barbouche MR, Bejaoui M, Hariz MB, Dellagi K. Two novel frame shift, recurrent and de novomutations in the ITGB2 (CD18) genecausing leukocyte adhesion deficiency in a highly inbred North African population. J Biomed Biotechnol. 2001;1(3):114–21.PubMedCentralPubMedCrossRef Fathallah DM, Jamal T, Barbouche MR, Bejaoui M, Hariz MB, Dellagi K. Two novel frame shift, recurrent and de novomutations in the ITGB2 (CD18) genecausing leukocyte adhesion deficiency in a highly inbred North African population. J Biomed Biotechnol. 2001;1(3):114–21.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Bejaoui M, Barbouche MR, Sassi A, Larguche B, Miladi N, Bouguerra A, et al. Primary immunodeficiency in Tunisia: study of 152cases. Arch Pediatr. 1997;4(9):827–31.PubMedCrossRef Bejaoui M, Barbouche MR, Sassi A, Larguche B, Miladi N, Bouguerra A, et al. Primary immunodeficiency in Tunisia: study of 152cases. Arch Pediatr. 1997;4(9):827–31.PubMedCrossRef
26.
Zurück zum Zitat Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.PubMedCrossRef Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.PubMedCrossRef
28.
Zurück zum Zitat Ailal F, Benhsaien I, Amenzoui N, Kili A, Jeddane L, Najib J, et al. Evoquer, explorer et diagnostiquer un déficit immunitaire primitif. Rev Marocaine Mal l’Enfant. 2012;28:46–52. Ailal F, Benhsaien I, Amenzoui N, Kili A, Jeddane L, Najib J, et al. Evoquer, explorer et diagnostiquer un déficit immunitaire primitif. Rev Marocaine Mal l’Enfant. 2012;28:46–52.
29.
Zurück zum Zitat Admou B, Haouach K, Ailal F, Benhsaine I, Barbouch MR, Bejaoui M, et al. Déficits immunitaires primitifs: approche diagnostique pour les pays émergents. Immunol Anal Biol Spécialisée. 2010. doi:10.1016/j.immbio.2010.09.003. Admou B, Haouach K, Ailal F, Benhsaine I, Barbouch MR, Bejaoui M, et al. Déficits immunitaires primitifs: approche diagnostique pour les pays émergents. Immunol Anal Biol Spécialisée. 2010. doi:10.​1016/​j.​immbio.​2010.​09.​003.
30.
Zurück zum Zitat Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013. doi:10.1007/s10875-013-9901-6. Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013. doi:10.​1007/​s10875-013-9901-6.
Metadaten
Titel
First Report on the Moroccan Registry of Primary Immunodeficiencies: 15 Years of Experience (1998–2012)
verfasst von
A. A. Bousfiha
L. Jeddane
N. El Hafidi
N. Benajiba
N. Rada
J. El Bakkouri
A. Kili
S. Benmiloud
I. Benhsaien
I. Faiz
O. Maataoui
Z. Aadam
A. Aglaguel
L. Ait Baba
Z. Jouhadi
R. Abilkassem
M. Bouskraoui
M. Hida
J. Najib
H. Salih Alj
F. Ailal
For the Moroccan Society for Primary Immunodeficiencies (MSPID)
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 4/2014
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-0005-8

Weitere Artikel der Ausgabe 4/2014

Journal of Clinical Immunology 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.